289 related articles for article (PubMed ID: 27738759)
41. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H
J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706
[TBL] [Abstract][Full Text] [Related]
42. Comparative Characteristics of Napsin A, TTF 1 and EGFR Mutation Expression in Mucinous Lung Cell Carcinomas.
Genova SN; Belovezhdov VT; Bichev SN; Danev VH
Folia Med (Plovdiv); 2017 Jun; 59(2):174-182. PubMed ID: 28704186
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.
Kadota K; Villena-Vargas J; Yoshizawa A; Motoi N; Sima CS; Riely GJ; Rusch VW; Adusumilli PS; Travis WD
Am J Surg Pathol; 2014 Apr; 38(4):448-60. PubMed ID: 24472852
[TBL] [Abstract][Full Text] [Related]
44. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
Takamochi K; Oh S; Matsuoka J; Suzuki K
Lung Cancer; 2012 Mar; 75(3):313-20. PubMed ID: 22209037
[TBL] [Abstract][Full Text] [Related]
45. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
46. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O; Cardona AF; Corrales L; Campos-Parra AD; Sánchez-Reyes R; Amieva-Rivera E; Rodríguez J; Vargas C; Carranza H; Otero J; Karachaliou N; Astudillo H; Rosell R;
Lung Cancer; 2015 Feb; 87(2):169-75. PubMed ID: 25558790
[TBL] [Abstract][Full Text] [Related]
47. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
48. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
49. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Ogata SY; Sato T; Tamura G
Ann Thorac Surg; 2014 Aug; 98(2):453-8. PubMed ID: 24961844
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
[TBL] [Abstract][Full Text] [Related]
51. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y
Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499
[TBL] [Abstract][Full Text] [Related]
52. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
53. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
[TBL] [Abstract][Full Text] [Related]
54. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
[TBL] [Abstract][Full Text] [Related]
55. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
56. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.
Calvayrac O; Pradines A; Raymond-Letron I; Rouquette I; Bousquet E; Lauwers-Cances V; Filleron T; Cadranel J; Beau-Faller M; Casanova A; Milia J; Favre G; Mazières J
Clin Cancer Res; 2014 Dec; 20(24):6541-50. PubMed ID: 25320360
[TBL] [Abstract][Full Text] [Related]
57. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.
Ha SY; Choi SJ; Cho JH; Choi HJ; Lee J; Jung K; Irwin D; Liu X; Lira ME; Mao M; Kim HK; Choi YS; Shim YM; Park WY; Choi YL; Kim J
Oncotarget; 2015 Mar; 6(7):5465-74. PubMed ID: 25760072
[TBL] [Abstract][Full Text] [Related]
58. The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma.
Deng H; Liu J; Duan X; Liu Y
Pathol Res Pract; 2018 Mar; 214(3):450-454. PubMed ID: 29496311
[TBL] [Abstract][Full Text] [Related]
59. Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old.
Forest F; Patoir A; Dal-Col P; Da Cruz V; Camy F; Stachowicz ML; Bayle-Bleuez S; Fournel P; Karpathiou G; Péoc'h M
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):667-671. PubMed ID: 30095461
[TBL] [Abstract][Full Text] [Related]
60. Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma.
Sasada S; Miyata Y; Mimae T; Mimura T; Okada M
Ann Thorac Surg; 2015 Dec; 100(6):2079-86. PubMed ID: 26298165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]